ARCH Venture Management, LLC - Q1 2023 holdings

$207 Million is the total value of ARCH Venture Management, LLC's 8 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 25.0% .

 Value Shares↓ Weighting
 EQRX, INC.$70,490,628
-21.1%
36,335,3750.0%34.02%
+48.6%
DNLI SellDENALI THERAPEUTICS, INC.$59,183,977
-42.0%
2,568,749
-30.0%
28.57%
+9.3%
 ERASCA, INC.$33,277,218
-30.2%
11,055,5540.0%16.06%
+31.6%
VERV  VERVE THERAPEUTICS, INC.$28,967,026
-25.5%
2,008,8090.0%13.98%
+40.4%
KRTX SellKARUNA THERAPEUTICS, INC.$5,449,200
-94.6%
30,000
-94.2%
2.63%
-89.8%
OMIC  SINGULAR GENOMICS SYSTEMS, INC.$4,596,700
-39.8%
3,798,9260.0%2.22%
+13.4%
NTRA NewNATERA, INC.$3,577,76464,441
+100.0%
1.73%
 UNITY BIOTECHNOLOGY, INC.$1,637,852
-40.5%
1,004,8170.0%0.79%
+12.2%
MTCR ExitMETACRINE, INC.$0-2,940,503
-100.0%
-0.34%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2023-05-15
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
RUBIUS THERAPEUTICS, INC.12Q3 202265.5%
EQRX, INC.8Q3 202352.4%
ERASCA, INC.8Q3 202318.8%
VERVE THERAPEUTICS, INC.8Q3 202323.3%
CHIASMA INC8Q3 202025.7%
SINGULAR GENOMICS SYSTEMS, INC.8Q3 20234.6%
KURA ONCOLOGY INC7Q2 202027.6%
KARUNA THERAPEUTICS, INC.6Q1 202352.8%
DENALI THERAPEUTICS, INC.6Q3 202328.6%
SYROS PHARMACEUTICALS INC5Q3 202043.8%

View ARCH Venture Management, LLC's complete holdings history.

Latest filings
TypeFiled
13F-HR2024-02-14
13F-HR2023-11-14
13F-HR2023-08-09
13F-HR2023-05-15
13F-HR2023-02-14
13F-HR2022-11-10
13F-HR2022-08-15
13F-HR/A2022-05-27
13F-HR2022-05-13
13F-HR2022-02-14

View ARCH Venture Management, LLC's complete filings history.

Compare quarters

Export ARCH Venture Management, LLC's holdings